Trial Profile

Phase II Trial Assessing Neoadjuvant Therapy With FEC 100 Followed by Taxotere (Docetaxel) Plus Vectibix (Panitumumab) in Patients With Operable, HR and Her-2 Negative Breast Cancer. TVA Study.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 13 May 2014

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Panitumumab (Primary) ; Cyclophosphamide; Docetaxel; Epirubicin; Fluorouracil
Indications Advanced breast cancer; Early breast cancer; Triple negative breast cancer
Focus Biomarker; Therapeutic Use
Acronyms TVA

Most Recent Events

14 Dec 2013 Results presented at the 36th Annual San Antonio Breast Cancer Symposium.
28 Jun 2012 Companies added in the association field as reported by EudraCT.
18 Jan 2012 Actual patient number (62) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com